Genes and coronary heart disease

Revista Espanola de Cardiologia

Volumn 55, Issue 4, 2002, Pages 413-431

  Navarro López, Francisco ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Atherosclerosis; Coronary heart disease; Molecular genetics; Mutations; Polymorphisms

Indexed keywords

CHOLESTEROL; ENZYME; INSULIN; LIPID; PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY RISK; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MULTIFACTORIAL GENETIC DISORDER; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PREDICTION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STRESS; THROMBOSIS; TOBACCO; VASCULAR ENDOTHELIUM; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETICS; HYPERTENSION;

CORONARY DISEASE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; THROMBOSIS;

EID: 0242709663     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(02)76620-7     Document Type: Review

References (103)

1. The increased risk of death from ischaemic heart disease in first degree relatives of 121 men and 96 women in ischaemic heart disease
2. Genetic susceptibility to death from coronary heart disease in study of twins
3. Genética y medicina molecular en cardiología
4. Genetics of atherosclerosis
5. Atherosclerosis
6. Genotype and risk of coronary heart disease
7. Lipids and vascular disease
8. A receptor mediated pathway for cholesterol homeostasis
9. Importance of HDL choresterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecular defined heterozygous familial hypercholesterolemia
10. Familial hypercholesterolaemia in Finland: Common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group
11. Pvu II intron 15 polymorphism at the LDL receptor gene is associated with differences in serum lipid concentrations in subjects with low and high risk for coronary artery disease from Brazil
12. Association of insertion/deletion gene polymorphism of the apolipoprotein B signal peptide with myocardial infarction
13. Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study
14. Apoplipoprotein E genotype: Epsilon32 women are protected while epsilon43 and epsilon44 man are susceptible to ischemic heart disease: The Copenhagen City Heart Study
15. Apolipoprotein E alleles and risk of coronary disease: A meta-analysis
16. The apolipoprotein E4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. A substudy of the Scandinavian Simvastatin Survival Study (4S)
17. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
18. Apoliporotein E and B polymorphisms-longevity factors assessed in nonagenarians
19. Polymorphisms of the genes encoding apoproteins A-I, B, C-III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Common alleles of the apoprotein E gene show the greatest regulatory impact
20. Lipoprotein(a) and atherogenesis
21. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
22. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a population sample of middle aged man
23. High density lipoproteins and arteriosclerosis. Role of cholesterol eflux and reverse cholesterol transport
24. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis
25. Tryglicerides as a risk factor for coronary artery disease
26. Lipoprotein lipase variants asparagine 291-serine aspartic acid 9-asparagine determine elevated plasma triglyceride concentrations studies in the fasting and postprandial stattes
27. Postprandial lipaemia
28. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: A novel Gly230 Arg mutation (LCAT[Fin]) of lecithin: Cholesterol acyltransferase (LCAT) accounts for 5% of cases cholesterol levels
29. The role of a common variant the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
30. Alcohol intake modulates the effect of a polymorphism of the cholesterol ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction
31. Paraoxonasa-genes and disease
32. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
33. The Gln/Arg polymorphism of human paraoxonasa (PON192) is not related to myocardial infarction in the ECTIM study
34. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
35. Risk of myocardial infarction associated with Gln/Arg192 polymorphism in the human paroxonase gene and diabetes mellitus
36. Tobacco smoking modifies association between Gln-Arg 192 polymorphism of human paraoxonase (PON 192) and risk of myocardial infarction
37. A novel polymorphism in promoter region of ATP binding transporter gene and plasma lipids, severity, progression and regression of coronary atherosclerosis and response to therapy
38. Variations of the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variations in plasma HDL cholesterol levels
39. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease
40. Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease: The CORGENE study
41. Antiotensinogen mutations and risk for ischemic heart disease, myocardial infarction and ischemic cerebrovascular disease
42. Deletion polymorphism and the angiotensin-converting enzime gene is a potent risk factor for myocardial infarction
43. A prospective evaluation of an angiotensin-converting-enzime gene polymorphism and the risk of ischemic heart disease
44. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzime gene with myocardial infarction
45. ACE en polymorphism in cardiovascular disease. Meta-analysis of small and large studies in whites
46. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5,000 cases and 6,000 controls. (ISIS) Collaboration
47. Angiotensin-converting enzime and angiotensin II receptor 1 polymorphism: Association with early coronary disease
48. Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphism
49. Deletion type allele of the angiotensin converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombosis Study Investigators
50. The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction
51. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: A major risk factor and a marker of risk for coronary stent restenosis
52. The angiotensin-converting enzyme and angiotensin converting II type I receptor gene as candidate gene for microalbuminuria. A study in non-diabetic and non-insulin diabetic subjects
53. Insertion/deletion polymorphism of the angiotensin-converting-enzyme gene is strongly associated with coronary heart disease in non-insuline-dependent diabetes mellitus
54. Evidence for association and genetic linkage of the angiotensin converting enzime locus with hypertension and blood pressure in men but not in women in the Framingham Heart Study
55. Association between a deletion polymorphism of the angiotensin-converting-enzime gene and left ventricular hypertrophy
56. Angiotensin II type I receptor A1166 gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme the risk of these diseases
57. The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction
58. Chymase gene locus is not associated with myocardial infarction and is not linked to heart size or blood pressure
59. The chymase A(-1903)G gene polymorphism is not associated with the risk and extent of coronary heart disease
60. Activation of cardiac aldosterone production in rat myocardial infarction
61. Association between human aldosterone synthase (CYP11B2) gene polymorphism and left ventricular size, mass and function
62. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular hypertrophy of mechanical overload [resumen]
63. Analysis of promoter region polymorphism in the aldosterone synthase gen (CYP11B2) as a risk factor for myocardial infarction
64. Genetic polymorphisms in coronary artery disease [resumen]
65. Positional genomic analysis identifies the beta-2-adrenergic receptor gene as a susceptibility locus for human hypertension
66. Insuline resistance. The metabolic syndrome X
67. The deadly quartet. Upper body obesity, glucose intolerance, hypertrigliceridemia, and hypertension
68. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipemia y atherosclerotic cardiovascular disease
69. Atherogenic dislipemia and metabolic syndrome
70. Insuline resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles
71. A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease
72. Role of glucose and insuline resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study
73. Diabetes mellitus, inflamación y aterosclerosis coronaria: Perspectiva actual y futura
74. Hyperinsulinemia as an independent risk factor for ischemic heart disease
75. Temas actuales de biología vascular: Puesta al día para el siglo XXI
76. Polymorphism of the NADH/NADPH oxidasa p22 phox gene in patients with coronary artery disease
77. NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function
78. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine
79. A common variant of the endothelial nitric oxide synthase (Glu298 > Asp) is a major risk factor for coronary artery disease in the UK
80. A missens Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese
81. A quantitative analysis of plasma homocysteinne as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
82. Common methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase activity
83. Methylenetetradydrofolate reductase genotypes and predisposition to atherothrombotic disease: Evidence that all three MTHFR C677T genotypes confer different levels of risk
84. Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6
85. Effects of Interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection
86. Genetic variation at the chemokine receptors CCR5/CCr2 in myocardial infarction
87. C(-260) T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction
88. Beta fibrinogen gen polymorphism are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study
89. A common mutation (G-455-A) in the beta-fibrinogen is an independent predictor of plasma fibrinogen, a risk factor for ischemic heart disease
90. Bcl I polymorphism in the fibrinogen b-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients
91. Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction
92. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease
93. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
94. Factor XIII val34leu and the risk of myocardial infarction
95. Polimorfismo genético Val34Leu del factor XIII y riesgo de infarto agudo de miocardio precoz [resumen]
96. Plasminogen-activator inhibitor type I and coronary artery disease
97. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
98. The AG/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
99. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study
100. Platelet polymorphism and ischemic heart disease: Moving beyond traditional factors
101. Increased platelet aggregability associated with platelet GPIIIa P1A2 polymorphism. The Framingham Offspring study
102. Meta-analysis of the association of platelet glycoprotein P1A1/A2 polymorphism with myocardial infarction
103. Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions